How Has Mass Drug Administration with Dihydroartemisinin-piperaquine Impacted Molecular Markers of Drug Resistance? A Systematic Review

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2022 Jun 11

PMID 35690758

Authors

Sophie Moss

Emilia Manko

Sanjeev Krishna

Susana Campino

Taane G Clark

Anna Last

Affiliations

Soon will be listed here.

Abstract

The World Health Organization (WHO) recommends surveillance of molecular markers of resistance to anti-malarial drugs. This is particularly important in the case of mass drug administration (MDA), which is endorsed by the WHO in some settings to combat malaria. Dihydroartemisinin-piperaquine (DHA-PPQ) is an artemisinin-based combination therapy which has been used in MDA. This review analyses the impact of MDA with DHA-PPQ on the evolution of molecular markers of drug resistance. The review is split into two parts. Section I reviews the current evidence for different molecular markers of resistance to DHA-PPQ. This includes an overview of the prevalence of these molecular markers in Plasmodium falciparum Whole Genome Sequence data from the MalariaGEN Pf3k project. Section II is a systematic literature review of the impact that MDA with DHA-PPQ has had on the evolution of molecular markers of resistance. This systematic review followed PRISMA guidelines. This review found that despite being a recognised surveillance tool by the WHO, the surveillance of molecular markers of resistance following MDA with DHA-PPQ was not commonly performed. Of the total 96 papers screened for eligibility in this review, only 20 analysed molecular markers of drug resistance. The molecular markers published were also not standardized. Overall, this warrants greater reporting of molecular marker prevalence following MDA implementation. This should include putative pfcrt mutations which have been found to convey resistance to DHA-PPQ in vitro.

Citing Articles

Low prevalence of copy number variation in pfmdr1 and pfpm2 in Plasmodium falciparum isolates from southern Angola.

Duarte D, Manuel F, Dias A, Sacato E, Taleingue E, Daniel E Malar J. 2025; 24(1):5.

PMID: 39794826 PMC: 11720348. DOI: 10.1186/s12936-024-05240-2.

Inter-Species Pharmacokinetic Modeling and Scaling for Drug Repurposing of Pyronaridine and Artesunate.

Kang D, Kim J, Kim K, Cho S, Choi G, Cho H Int J Mol Sci. 2024; 25(13).

PMID: 39000107 PMC: 11241507. DOI: 10.3390/ijms25136998.

Nationwide spatiotemporal drug resistance genetic profiling from over three decades in Indian Plasmodium falciparum and Plasmodium vivax isolates.

Kojom Foko L, Narang G, Jakhan J, Tamang S, Moun A, Singh V Malar J. 2023; 22(1):236.

PMID: 37582796 PMC: 10428610. DOI: 10.1186/s12936-023-04651-x.

Antimalarial Drug Resistance: A Brief History of Its Spread in Indonesia.

Fitri L, Pawestri A, Winaris N, Endharti A, Khotimah A, Abidah H Drug Des Devel Ther. 2023; 17:1995-2010.

PMID: 37431492 PMC: 10329833. DOI: 10.2147/DDDT.S403672.

Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial.

Hutchins H, Bradley J, Pretorius E, Teixeira da Silva E, Vasileva H, Jones R BMJ Open. 2023; 13(7):e072347.

PMID: 37419638 PMC: 10335573. DOI: 10.1136/bmjopen-2023-072347.

References

Agrawal S, Moser K, Morton L, Cummings M, Parihar A, Dwivedi A . Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity. J Infect Dis. 2017; 216(4):468-476. PMC: 5853219. DOI: 10.1093/infdis/jix334. View

Veiga M, Ferreira P, Malmberg M, Jornhagen L, Bjorkman A, Nosten F . pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquine. Antimicrob Agents Chemother. 2012; 56(7):3615-9. PMC: 3393437. DOI: 10.1128/AAC.06350-11. View

Leroy D, Macintyre F, Adoke Y, Ouoba S, Barry A, Mombo-Ngoma G . African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker. Malar J. 2019; 18(1):126. PMC: 6457011. DOI: 10.1186/s12936-019-2756-4. View

Turkiewicz A, Manko E, Sutherland C, Diez Benavente E, Campino S, Clark T . Genetic diversity of the Plasmodium falciparum GTP-cyclohydrolase 1, dihydrofolate reductase and dihydropteroate synthetase genes reveals new insights into sulfadoxine-pyrimethamine antimalarial drug resistance. PLoS Genet. 2020; 16(12):e1009268. PMC: 7774857. DOI: 10.1371/journal.pgen.1009268. View

van der Pluijm R, Imwong M, Chau N, Hoa N, Thuy-Nhien N, Thanh N . Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019; 19(9):952-961. PMC: 6715822. DOI: 10.1016/S1473-3099(19)30391-3. View

Son D, Thuy-Nhien N, von Seidlein L, Phuc-Nhi T, Phu N, Tuyen N . The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc province, Vietnam: a pilot study. Malar J. 2017; 16(1):444. PMC: 5674731. DOI: 10.1186/s12936-017-2091-6. View

Le Thi D, Le N, Nguyen C, Phan Thi D, Na-Bangchang K . Pharmacokinetics of a five-day oral dihydroartemisinin monotherapy regimen in patients with uncomplicated falciparum malaria. Drug Metab Pharmacokinet. 2008; 23(3):158-64. DOI: 10.2133/dmpk.23.158. View

Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M . Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359(24):2619-20. DOI: 10.1056/NEJMc0805011. View

Ross L, Dhingra S, Mok S, Yeo T, Wicht K, Kumpornsin K . Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun. 2018; 9(1):3314. PMC: 6095916. DOI: 10.1038/s41467-018-05652-0. View

10.

Parobek C, Parr J, Brazeau N, Lon C, Chaorattanakawee S, Gosi P . Partner-Drug Resistance and Population Substructuring of Artemisinin-Resistant Plasmodium falciparum in Cambodia. Genome Biol Evol. 2017; 9(6):1673-1686. PMC: 5522704. DOI: 10.1093/gbe/evx126. View

11.

Witkowski B, Duru V, Khim N, Ross L, Saintpierre B, Beghain J . A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis. 2016; 17(2):174-183. PMC: 5266792. DOI: 10.1016/S1473-3099(16)30415-7. View

12.

Wang J, Zhang C, Chia W, Loh C, Li Z, Lee Y . Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015; 6:10111. PMC: 4703832. DOI: 10.1038/ncomms10111. View

13.

Some A, Zongo I, Compaore Y, Sakande S, Nosten F, Ouedraogo J . Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2014; 58(7):3660-5. PMC: 4068591. DOI: 10.1128/AAC.02406-14. View

14.

Conrad M, Mota D, Foster M, Tukwasibwe S, Legac J, Tumwebaze P . Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda. J Infect Dis. 2017; 216(8):1008-1017. PMC: 5853776. DOI: 10.1093/infdis/jix421. View

15.

Madanitsa M, Kalilani L, Mwapasa V, van Eijk A, Khairallah C, Ali D . Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized.... PLoS Med. 2016; 13(9):e1002124. PMC: 5021271. DOI: 10.1371/journal.pmed.1002124. View

16.

Dhingra S, Redhi D, Combrinck J, Yeo T, Okombo J, Henrich P . A Variant PfCRT Isoform Can Contribute to Resistance to the First-Line Partner Drug Piperaquine. mBio. 2017; 8(3). PMC: 5424201. DOI: 10.1128/mBio.00303-17. View

17.

Dhingra S, Small-Saunders J, Menard D, Fidock D . Plasmodium falciparum resistance to piperaquine driven by PfCRT. Lancet Infect Dis. 2019; 19(11):1168-1169. PMC: 6943240. DOI: 10.1016/S1473-3099(19)30543-2. View

18.

Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson R . Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect Dis. 2016; 17(2):164-173. PMC: 5564489. DOI: 10.1016/S1473-3099(16)30409-1. View

19.

Taylor A, Flegg J, Holmes C, Guerin P, Sibley C, Conrad M . Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Drug Sensitivity-Associated Haplotypes in Uganda. Open Forum Infect Dis. 2017; 4(1):ofw229. PMC: 5413987. DOI: 10.1093/ofid/ofw229. View

20.

Ansbro M, Jacob C, Amato R, Kekre M, Amaratunga C, Sreng S . Development of copy number assays for detection and surveillance of piperaquine resistance associated plasmepsin 2/3 copy number variation in Plasmodium falciparum. Malar J. 2020; 19(1):181. PMC: 7218657. DOI: 10.1186/s12936-020-03249-x. View